EDIT
MaterialsEditas Medicine Inc
Live · NASDAQ · May 8, Close
What's Moving EDIT Today?
No stock-specific AI insight has been generated for EDIT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
EDIT News
21 articles- EDIT's Q1 Loss Narrower Than Expected, Pipeline in FocusYahoo Finance·May 6, 2026
- Company News for May 6, 2026Yahoo Finance·May 6, 2026
- Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Editas Medicine Announces First Quarter 2026 Results and Business UpdatesYahoo Finance·May 5, 2026
- Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific ConferencesYahoo Finance·Apr 27, 2026
- Neutrolis Appoints Caren Deardorf as Chief Business & Strategy OfficerGlobeNewswire Inc.·Apr 15, 2026
- Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?Yahoo Finance·Apr 15, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarYahoo Finance·Apr 13, 2026
- Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?Yahoo Finance·Apr 8, 2026
- Why Investors Need to Take Advantage of These 2 Medical Stocks NowYahoo Finance·Apr 7, 2026
- Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 InterferenceYahoo Finance·Mar 27, 2026
- Is Editas Medicine Going to $0?Motley Fool·Mar 17, 2026
- Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401Marketbeat·Mar 15, 2026
- EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/YYahoo Finance·Mar 10, 2026
- Medicus Pharma Ltd. To Participate In The Longwood Miami CEO ForumYahoo Finance·Mar 10, 2026
- Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 9, 2026
- Editas: Q4 Earnings SnapshotYahoo Finance·Mar 9, 2026
- Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business UpdatesYahoo Finance·Mar 9, 2026
- Editas Medicine to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- Companies Like Editas Medicine (NASDAQ:EDIT) Could Be Quite RiskyYahoo Finance·Feb 9, 2026
- Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Dec 10, 2025
All 21 articles loaded
Price Data
Fundamentals
Trading
About Editas Medicine Inc
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.